Stereotactic radiosurgery shows promise for kidney cancer

October 31, 2012

CLEVELAND - A first-of-its-kind clinical trial conducted at University Hospitals (UH) Case Medical Center Seidman Cancer Center has shown encouraging results for the use of stereotactic radiosurgery to treat kidney cancer. This non-invasive treatment technique may represent a potential new non-surgical option for patients with this deadly disease who have limited treatment options.

Rod Ellis, MD, lead author of the study along with Lee Ponsky, MD, who is the Principal Investigator, presented results of a Phase 1 clinical trial in 20 patients with localized primary renal cancer at the 54th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in Boston. In the abstract titled "Stereotactic Radiosurgery for Renal Cancer: Phase I Safety and Toxicity" (embargoed Oct. 31, 7:00 am ET), Dr. Ellis presented data that 94 percent of patients treated in the study had decreased or stable disease, with limited side effects.

"This trial shows that low to moderate doses of stereotactic radiosurgery are safe for renal cancer patients who typically do not have surgical options," said Dr. Ellis, Clinical Director and Vice Chair for Clinical Affairs, Department of Radiation Oncology at UH Case Medical Center and Associate Professor of Radiation Oncology and Urology at Case Western Reserve University School of Medicine. "Based on these findings, this treatment represents a promising therapeutic option. Further studies are needed to determine safe levels for the maximum dosage and by doing so, we hope to find increased response and cure rates with this method."

"This study is a unique partnership between a surgeon and radiation oncologist, intended to offer patients a non-invasive, highly focused ablative radiation with surgical precision with little to no side effects," said Dr. Ponsky, Director, Urologic Oncology and Minimally Invasive Therapies at UH Case Medial Center and Associate Professor of Urology at Case Western Reserve School of Medicine. "We are very excited about these results and cautiously optimistic about the future potential of this therapy."

According to the American Cancer Society, there are about 65,000 new cases of kidney cancer each year in the U.S. and it is among the 10 most common cancers in both men and women. Treatment options typically include surgery or cryoablation (using cold therapy to destroy the tumor).

However, many patients are not surgical candidates and stereotactic radiosurgery provides a noninvasive alternative in just three treatments which requires no anesthesia or narcotics. Stereotactic radiosurgery is performed using Cyberknife, a robotic radiosurgery system which delivers targeted doses of radiation with sub-millimeter accuracy while minimizing damage to surrounding healthy tissue. This high-dose, focused radiation destroys tumor cells and stops cancer cells from growing.

This study followed patients from two to 41 months post-treatment using a four-part dose escalation schema. The response rate indicates that patients reacted well and had acceptable levels of treatment-related toxicity following stereotactic radiosurgery in all age groups from 58 to 92 years old. Based on these positive results, Drs. Ellis and Ponsky and a team of researchers have launched a follow-up phase two study for 12 additional patients with increased dosage to determine the most effective dosage. "This study builds upon our team's previous work as we continue to evaluate and define the role of radiosurgery for the safe and effective treatment of kidney tumors," said Dr. Ponsky, who holds the Leo and Charlotte Goldberg Chair in Advanced Surgical Therapies.

"Radiosurgery delivers a higher and more effective dose directly to the tumor site with less side effects than conventional radiation and has been very effective in treating other hard-to-reach tumors," said Dr. Ellis. "We are excited about its potential for kidney cancer patients and to be able to offer a non-invasive option."
-end-
Study co-authors include R.B. Patel, C. Kunos, Y. Zhang, J. Brindle, V. Kudithipudi, and D.A. Kaminsky. Trial funded by the Accuray Corporation, Sunnyvale, California.

About University Hospitals

University Hospitals serves the needs of patients through an integrated network of hospitals, outpatient centers and primary care physicians. At the core of our health system is University Hospitals Case Medical Center. The primary affiliate of Case Western Reserve University School of Medicine, University Hospitals Case Medical Center is home to some of the most prestigious clinical and research centers of excellence in the nation and the world, including cancer, pediatrics, women's health, orthopedics and spine, radiology and radiation oncology, neurosurgery and neuroscience, cardiology and cardiovascular surgery, organ transplantation and human genetics. Its main campus includes the internationally celebrated UH Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University. University Hospitals Case Medical Center is the 2012 recipient of the American Hospital Association - McKesson Quest for Quality Prize for its leadership and innovation in quality improvement and safety.

For more information, go to www.uhhospitals.org

University Hospitals Case Medical Center

Related Kidney Cancer Articles from Brightsurf:

Reducing urinary protein for patients with rare kidney disease slows kidney decline
New findings show that reducing the amount of protein in the urine of patients with focal segmental glomerulosclerosis can significantly slow declines in kidney function and extend time before patients' kidneys fail.

Acute kidney injury and end stage kidney disease in severe COVID-19
Many COVID-19 patients experience hematuria, proteinuria and elevated serum creatinine concentration early in the course of the disease.

Cutting off kidney cancer at its roots
Scientists at the MDC have discovered stem cells responsible for the most common form of kidney cancer.

Finding familiar pathways in kidney cancer
The famous cancer gene p53, which was thought to be less relevant in kidney cancer, may play a larger role than previously appreciated, suggesting new potential for treatment.

Root of childhood kidney cancer discovered
A fundamental change in our understanding of the childhood kidney cancer Wilms' tumor is on the horizon, after the discovery of its earliest genetic root by scientists at the Wellcome Sanger Institute and their collaborators.

Kidney-resident macrophages -- a role for healing during acute kidney injury?
Researchers have found that, during acute kidney injury in a mouse model, the kidney-resident macrophages are reprogrammed to a developmental state, resembling these same cells when they are found in newborn mice.

Antibodies to a retina protein to be used as a kidney cancer marker
Sechenov University together with their German colleagues suggest a new highly sensitive, quick, and pain-free method for diagnosing kidney cancer.

Revealed: 35 kidney genes linked to chronic kidney disease risk
An international study lead by University of Manchester scientists has discovered the identity of genes that predispose people to chronic kidney disease.

High-dose, high-precision radiation therapy safe, effective for solitary kidney cancer patients with only one kidney
Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one kidney as it is for those who have two, according to an analysis of the largest-ever, international dataset of solitary kidney patients to receive this emerging treatment.

Kidney cancer's developmental source revealed
In the first experiment of its kind, scientists have revealed the precise identity of cancer cells of the most common childhood and adult kidney cancers.

Read More: Kidney Cancer News and Kidney Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.